Despite the clamor to speed up the U.S. vaccination drive against COVID-19 and get the country back to normal, the first three months of the rollout suggest faster is not necessarily better.
FALLS CHURCH, Va. (FOX 5 DC) - A study out of Northern Virginia shows children had a surprisingly high rate of COVID-19 antibodies.
Inova Health System partnered with Virginia Department of Health and George Mason University to look at the rate of COVID-19 in children. It was done in the Fall.
...a number of people ...are reporting that the post-Covid symptoms they’ve experienced for months have begun improving, sometimes significantly, after they got the vaccine. It’s a phenomenon that doctors and scientists are watching closely, but as with much about the yearlong coronavirus pandemic, there are many uncertainties.
Scientists are only beginning to study any potential effect of vaccines on long Covid symptoms. Anecdotes run the gamut: Besides those who report feeling better after the shots, many people say they have experienced no change and a small number say they feel worse.
The European Union proposed a Covid-19 certificate on Wednesday that would allow people to travel more freely, a move aimed at saving the summer tourist season for member states that depend on it economically.
The proposed document, known as a Digital Green Certificate, would allow residents of member nations to travel at will within the bloc if they have proof of Covid-19 vaccination, a negative test result or a documented recovery from the coronavirus.
The certificates would be free and would be available in digital or paper format.
“The Digital Green Certificate will not be a precondition to free movement, and it will not discriminate in any way,” said Didier Reynders, the bloc’s top official for justice, adding that the aim was to “gradually restore free movement within the E.U. and avoid fragmentation.”
States, airlines and tech companies are pressuring the Biden administration to develop a federal standard for vaccine passports — a policy that could speed the economic recovery but might also discriminate against disadvantaged groups and jeopardize privacy.
(Reuters) - Moderna Inc has begun dosing patients in a mid-to-late stage study of its COVID-19 vaccine, mRNA-1273, in children aged six months to less than 12 years, the company said on Tuesday.
Recent Comments